JP5160081B2 - 酸化セルロースおよびヒト組換えコラーゲンを含有している創傷包帯 - Google Patents
酸化セルロースおよびヒト組換えコラーゲンを含有している創傷包帯 Download PDFInfo
- Publication number
- JP5160081B2 JP5160081B2 JP2006332282A JP2006332282A JP5160081B2 JP 5160081 B2 JP5160081 B2 JP 5160081B2 JP 2006332282 A JP2006332282 A JP 2006332282A JP 2006332282 A JP2006332282 A JP 2006332282A JP 5160081 B2 JP5160081 B2 JP 5160081B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- wound dressing
- human recombinant
- wound
- recombinant collagen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000008186 Collagen Human genes 0.000 title claims description 102
- 108010035532 Collagen Proteins 0.000 title claims description 102
- 229920001436 collagen Polymers 0.000 title claims description 102
- 229920002201 Oxidized cellulose Polymers 0.000 title claims description 45
- 229940107304 oxidized cellulose Drugs 0.000 title claims description 45
- 206010052428 Wound Diseases 0.000 claims description 118
- 208000027418 Wounds and injury Diseases 0.000 claims description 118
- 239000000203 mixture Substances 0.000 claims description 79
- 239000000463 material Substances 0.000 claims description 55
- 239000000835 fiber Substances 0.000 claims description 11
- 239000004627 regenerated cellulose Substances 0.000 claims description 9
- 230000029663 wound healing Effects 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 238000000034 method Methods 0.000 description 20
- 239000010410 layer Substances 0.000 description 18
- 239000006185 dispersion Substances 0.000 description 17
- 241000283690 Bos taurus Species 0.000 description 16
- 230000001684 chronic effect Effects 0.000 description 15
- 210000002950 fibroblast Anatomy 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 238000011282 treatment Methods 0.000 description 13
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 11
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 11
- 210000004207 dermis Anatomy 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 239000012530 fluid Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 239000013641 positive control Substances 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 102000001187 Collagen Type III Human genes 0.000 description 7
- 108010069502 Collagen Type III Proteins 0.000 description 7
- 239000004744 fabric Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 102000012422 Collagen Type I Human genes 0.000 description 6
- 108010022452 Collagen Type I Proteins 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 239000002002 slurry Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000000853 adhesive Substances 0.000 description 5
- 230000001070 adhesive effect Effects 0.000 description 5
- 229940096422 collagen type i Drugs 0.000 description 5
- 230000002500 effect on skin Effects 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 206010056340 Diabetic ulcer Diseases 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 208000000558 Varicose Ulcer Diseases 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000005057 Hexamethylene diisocyanate Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000004210 Pressure Ulcer Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000002250 absorbent Substances 0.000 description 3
- 230000002745 absorbent Effects 0.000 description 3
- 239000012790 adhesive layer Substances 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 239000012131 assay buffer Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000002439 hemostatic effect Effects 0.000 description 3
- RRAMGCGOFNQTLD-UHFFFAOYSA-N hexamethylene diisocyanate Chemical compound O=C=NCCCCCCN=C=O RRAMGCGOFNQTLD-UHFFFAOYSA-N 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000001626 skin fibroblast Anatomy 0.000 description 3
- -1 starch glycolate) Polymers 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 2
- 229920000297 Rayon Polymers 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 239000000515 collagen sponge Substances 0.000 description 2
- GLNDAGDHSLMOKX-UHFFFAOYSA-N coumarin 120 Chemical compound C1=C(N)C=CC2=C1OC(=O)C=C2C GLNDAGDHSLMOKX-UHFFFAOYSA-N 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- WFPZPJSADLPSON-UHFFFAOYSA-N dinitrogen tetraoxide Chemical compound [O-][N+](=O)[N+]([O-])=O WFPZPJSADLPSON-UHFFFAOYSA-N 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 229920002313 fluoropolymer Polymers 0.000 description 2
- 239000004811 fluoropolymer Substances 0.000 description 2
- 150000004676 glycans Polymers 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002964 rayon Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- XMTQQYYKAHVGBJ-UHFFFAOYSA-N 3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA Chemical compound CN(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XMTQQYYKAHVGBJ-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- GUTLYIVDDKVIGB-OUBTZVSYSA-N Cobalt-60 Chemical compound [60Co] GUTLYIVDDKVIGB-OUBTZVSYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- LOPTYBITJCPCRX-WURLWEPXSA-N N1[C@@H](CCC1)C(=O)O.NCC(=O)O.N[C@@H](CC(C)C)C(=O)O.N1[C@@H](CCC1)C(=O)O.C(CCC(=O)O)(=O)NCC(=O)O Chemical compound N1[C@@H](CCC1)C(=O)O.NCC(=O)O.N[C@@H](CC(C)C)C(=O)O.N1[C@@H](CCC1)C(=O)O.C(CCC(=O)O)(=O)NCC(=O)O LOPTYBITJCPCRX-WURLWEPXSA-N 0.000 description 1
- CBSMMWZXXSOBSP-FJBWBJDGSA-N NC1=CC=C2C(=CC(OC2=C1)=O)C.N1[C@@H](CCC1)C(=O)O.NCC(=O)O.N[C@@H](CC(C)C)C(=O)O.N1[C@@H](CCC1)C(=O)O.C(CCC(=O)O)(=O)NCC(=O)O Chemical compound NC1=CC=C2C(=CC(OC2=C1)=O)C.N1[C@@H](CCC1)C(=O)O.NCC(=O)O.N[C@@H](CC(C)C)C(=O)O.N1[C@@H](CCC1)C(=O)O.C(CCC(=O)O)(=O)NCC(=O)O CBSMMWZXXSOBSP-FJBWBJDGSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 229920005830 Polyurethane Foam Polymers 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- 102000004079 Prolyl Hydroxylases Human genes 0.000 description 1
- 108010043005 Prolyl Hydroxylases Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- KIPLYOUQVMMOHB-MXWBXKMOSA-L [Ca++].CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O.CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O Chemical compound [Ca++].CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O.CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O KIPLYOUQVMMOHB-MXWBXKMOSA-L 0.000 description 1
- 238000012084 abdominal surgery Methods 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229920006318 anionic polymer Polymers 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000002737 cell proliferation kit Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000001246 colloidal dispersion Methods 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000012520 frozen sample Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 150000002576 ketones Chemical group 0.000 description 1
- 238000009940 knitting Methods 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000000673 metalloproteinaselike Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229960003128 mupirocin Drugs 0.000 description 1
- 229930187697 mupirocin Natural products 0.000 description 1
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- WQVJHHACXVLGBL-GOVYWFKWSA-N polymyxin B1 Polymers N1C(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)CCCC[C@H](C)CC)CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1CC1=CC=CC=C1 WQVJHHACXVLGBL-GOVYWFKWSA-N 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 229920006264 polyurethane film Polymers 0.000 description 1
- 239000011496 polyurethane foam Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000007388 punch biopsy Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 125000006853 reporter group Chemical group 0.000 description 1
- 238000003385 ring cleavage reaction Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 229920005573 silicon-containing polymer Polymers 0.000 description 1
- 150000003378 silver Chemical class 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229940071117 starch glycolate Drugs 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229960004291 sucralfate Drugs 0.000 description 1
- MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229940063650 terramycin Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 239000012815 thermoplastic material Substances 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 239000003357 wound healing promoting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
- A61L15/325—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/20—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing organic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/225—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/425—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Dispersion Chemistry (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
凍結乾燥した、コラーゲン/ORCのスポンジを以下のように調製した。
ヒト組換えコラーゲン/繊維質ORCのスポンジを、参考例1において記載されているように、調整したが、そのコラーゲンを、等量のヒト組換えコラーゲンのフラクションにより、置き換えている。このヒト組換えコラーゲンは、カリフォルニア州、94080、サウス・サン・フランシスコ、ゲートウエイ・ブールバード225(225 Gateway Boulevard, South San Francisco, California, 94080)所在の、フィブロゲン・インコーポレイテッド(Fibrogen Inc.)から、入手されている。このコラーゲンは、遺伝的に修飾されている酵母により製造され、前記ウシの材料の密度(consistency)と同等の密度を達成するために、架橋されている。また、このヒト組換えコラーゲンは、トリプシン消化の受けやすさにおいて、ウシコラーゲンと同等である。I型:III型の、ヒト組換えコラーゲン、の異なる比率を伴う多数の異なるスポンジを作製した。
ヒト皮膚線維芽細胞の増殖アッセイを以下のように行なった。
6人の異なる患者からの創傷流体の凍結したサンプルを解凍して適宜に希釈した。
(1)創傷包帯用組成物において、
ヒト組換えコラーゲンと、
酸化セルロースと、
を含有している、創傷包帯用組成物。
(2)実施態様1に記載の創傷包帯用組成物において、
前記ヒト組換えコラーゲン、および前記酸化セルロースは、前記創傷包帯用組成物の中に完全に混合されている、創傷包帯用組成物。
(3)実施態様1または2に記載の創傷包帯用組成物において、
前記酸化セルロースは、分散されている繊維、または、分散されている粉末、の形態である、創傷包帯用組成物。
(4)実施態様1〜3のいずれかに記載の創傷包帯用組成物において、
前記酸化セルロースは、酸化再生セルロース(oxidized regenerated cellulose)(ORC)を含む、創傷包帯用組成物。
(5)実施態様1〜4のいずれかに記載の無菌の凍結乾燥したスポンジにおいて、
前記ヒト組換えコラーゲンは、I型ヒト組換えコラーゲン、III型ヒト組換えコラーゲン、および、これらの混合物、から選択される、無菌の凍結乾燥したスポンジ。
約50:50〜約100:0、好ましくは約70:30〜約90:10の比率で、I型ヒト組換えコラーゲン、および、III型ヒト組換えコラーゲン、を含有している、無菌の凍結乾燥したスポンジ。
(7)実施態様1〜6のいずれかに記載の創傷包帯用組成物において、
前記酸化セルロース、および前記ヒト組換えコラーゲンは合わせて、乾燥重量に基いて、前記材料の少なくとも25重量%を構成している、創傷包帯用組成物。
(8)実施態様7に記載の創傷包帯用組成物において、
前記酸化セルロース、および前記ヒト組換えコラーゲンは合わせて、乾燥重量に基いて、前記材料の少なくとも50重量%を構成している、創傷包帯用組成物。
(9)実施態様1〜8のいずれかに記載の創傷包帯用組成物において、
前記組成物が、1種類以上の創傷治癒治療用の物質を、乾燥重量に基いて、約0.01〜約5重量%で、さらに含有している、創傷包帯用組成物。
(10)実施態様1〜9のいずれかに記載の創傷包帯用組成物において、
前記ヒト組換えコラーゲンと前記酸化セルロースとの重量比率は、1:10〜10:1である、創傷包帯用組成物。
前記ヒト組換えコラーゲンと前記酸化セルロースとの重量比率は、1:4〜4:1の範囲である、創傷包帯用組成物。
(12)創傷包帯において、
実施態様1〜11のいずれかに記載の創傷包帯用組成物、
を含有している、創傷包帯。
(13)実施態様12に記載の創傷包帯において、
前記創傷包帯は、無菌であり、かつ、微生物不透過性の容器の中に包装されている、創傷包帯。
(14)実施態様1〜11のいずれかに記載の創傷包帯用組成物の使用において、
創傷の治療のための包帯の調製のための、使用。
(15)実施態様14に記載の使用において、
前記創傷は、慢性の創傷である、使用。
前記慢性の創傷は、静脈性潰瘍、褥瘡、および、糖尿病性潰瘍、からなる群から選択される、使用。
Claims (12)
- 創傷包帯用組成物において、
ヒト組換えコラーゲンと、
酸化セルロースと、
を含有し、
前記ヒト組換えコラーゲンは、I型ヒト組換えコラーゲンとIII型ヒト組換えコラーゲンとの混合物から選択され、
I型ヒト組換えコラーゲンとIII型ヒト組換えコラーゲンとの重量比率は、70:30より大きい、創傷包帯用組成物。 - 請求項1に記載の創傷包帯用組成物において、
前記ヒト組換えコラーゲン、および前記酸化セルロースは、前記創傷包帯用組成物の中に混合されている、創傷包帯用組成物。 - 請求項1に記載の創傷包帯用組成物において、
前記酸化セルロースは、分散されている繊維、または、分散されている粉末、の形態である、創傷包帯用組成物。 - 請求項3に記載の創傷包帯用組成物において、
前記酸化セルロースは、酸化再生セルロース(ORC)を含む、創傷包帯用組成物。 - 請求項1に記載の創傷包帯用組成物において、
80:20の比率で、I型ヒト組換えコラーゲン、および、III型ヒト組換えコラーゲン、を含有している、創傷包帯用組成物。 - 請求項1または5に記載の創傷包帯用組成物において、
前記酸化セルロース、および前記ヒト組換えコラーゲンは合わせて、乾燥重量に基いて、前記材料の少なくとも25重量%を構成している、創傷包帯用組成物。 - 請求項1または5に記載の創傷包帯用組成物において、
前記酸化セルロース、および前記ヒト組換えコラーゲンは合わせて、乾燥重量に基いて、前記材料の少なくとも50重量%を構成している、創傷包帯用組成物。 - 請求項4に記載の創傷包帯用組成物において、
前記組成物が、1種類以上の創傷治癒治療用の物質を、乾燥重量に基いて、0.01〜5重量%で、さらに含有している、創傷包帯用組成物。 - 請求項4に記載の創傷包帯用組成物において、
前記ヒト組換えコラーゲンと前記酸化セルロースとの重量比率は、1:10〜10:1である、創傷包帯用組成物。 - 請求項9に記載の創傷包帯用組成物において、
前記ヒト組換えコラーゲンと前記酸化セルロースとの重量比率は、1:4〜4:1の範囲である、創傷包帯用組成物。 - 創傷包帯において、
請求項1または5に記載の創傷包帯用組成物、
を含有している、創傷包帯。 - 創傷包帯のパッケージにおいて、
(a)微生物不透過性の容器と、
(b)その中に包装され、かつ、無菌である、請求項11に記載の創傷包帯と、
を備えている、創傷包帯のパッケージ。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0525130.1 | 2005-12-09 | ||
GB0525130A GB2433029A (en) | 2005-12-09 | 2005-12-09 | Wound dressings comprising oxidized cellulose and human recombinant collagen |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007160092A JP2007160092A (ja) | 2007-06-28 |
JP5160081B2 true JP5160081B2 (ja) | 2013-03-13 |
Family
ID=35735850
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006332282A Active JP5160081B2 (ja) | 2005-12-09 | 2006-12-08 | 酸化セルロースおよびヒト組換えコラーゲンを含有している創傷包帯 |
Country Status (7)
Country | Link |
---|---|
US (1) | US7833790B2 (ja) |
EP (1) | EP1795210B1 (ja) |
JP (1) | JP5160081B2 (ja) |
AU (1) | AU2006249270B8 (ja) |
CA (1) | CA2568455C (ja) |
ES (1) | ES2373676T3 (ja) |
GB (1) | GB2433029A (ja) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2181721A3 (de) * | 2006-11-06 | 2010-05-19 | Lohmann & Rauscher GmbH & Co. KG | Produkt zur Versorgung von Entzündungen, Druckstellen und/oder Aphten im Oralbereich sowie Verwendung eines solchen Produkts |
US8071663B2 (en) * | 2008-02-29 | 2011-12-06 | Ethicon, Inc. | Medically acceptable formulation of a diisocyanate terminated macromer for use as an internal adhesive or sealant |
US8324292B2 (en) * | 2008-02-29 | 2012-12-04 | Ethicon, Inc. | Medically acceptable formulation of a diisocyanate terminated macromer for use as an internal adhesive or sealant |
GB2459099A (en) * | 2008-04-08 | 2009-10-14 | Ethicon Inc | Genetic markers of wound development |
CN104491845A (zh) | 2008-04-18 | 2015-04-08 | 科尔普兰特有限公司 | 产生和使用原胶原的方法 |
US20100172889A1 (en) * | 2008-12-05 | 2010-07-08 | Catchmark Jeffrey M | Degradable biomolecule compositions |
DK2380979T3 (da) | 2008-12-22 | 2015-06-22 | Univ Hokkaido Nat Univ Corp | Proteinstof med trippelhelixstruktur samt fremgangsmåde til dets fremstilling |
US8349354B2 (en) * | 2009-09-22 | 2013-01-08 | Ethicon, Inc. | Composite layered hemostasis device |
US20110086236A1 (en) * | 2009-10-13 | 2011-04-14 | The Penn State Research Foundation | Composites containing polypeptides attached to polysaccharides and molecules |
GB201008404D0 (en) * | 2010-05-20 | 2010-07-07 | Fujifilm Mfg Europe Bv | Hemostatic compositions |
US9782457B2 (en) * | 2011-10-07 | 2017-10-10 | Tissue Repair Company | Flowable formulations for tissue repair and regeneration |
GB201207617D0 (en) * | 2012-05-02 | 2012-06-13 | Systagenix Wound Man Ip Co Bv | Wound dressings |
EP3024887B1 (en) | 2013-07-26 | 2023-11-22 | The Penn State Research Foundation | Method for preparation of polymer compositions and coatings |
CN106659818B (zh) * | 2014-08-11 | 2021-01-22 | 凯希特许有限公司 | 用于与负压伤口治疗一起使用的蛋白酶调节伤口接口层 |
CN104667335B (zh) * | 2015-01-27 | 2018-02-02 | 山西锦波生物医药股份有限公司 | 皮肤屏障功能或痔的重组人源胶原蛋白产品及制备方法 |
US10517989B1 (en) * | 2016-11-23 | 2019-12-31 | Jonathan F. Arnold | Enhanced medical dressing apparatus, system, and method |
WO2019027933A1 (en) * | 2017-07-31 | 2019-02-07 | Kci Usa, Inc. | BIOREABORBABLE DRESSING WITH STRUCTURAL SUPPORT |
US11877910B2 (en) * | 2017-11-03 | 2024-01-23 | Systagenix Wound Management, Limited | Nutrient-enriched dressing |
US20210361820A1 (en) * | 2018-01-31 | 2021-11-25 | Systagenix Wound Management, Limited | Antimicrobial composition, dressing, dressing components, and method |
US20210146002A1 (en) * | 2018-02-02 | 2021-05-20 | Kci Licensing, Inc. | Unique combination of natural biopolymers for advanced wound dressing |
EP3823680B1 (en) * | 2018-07-16 | 2024-03-06 | Systagenix Wound Management, Limited | Nitric oxide producing collagen/orc dressing |
US20230029576A1 (en) * | 2020-01-07 | 2023-02-02 | Kci Licensing, Inc. | Means to improve usability of a wound insert for application to deep wounds |
CN111467560B (zh) * | 2020-05-27 | 2022-08-05 | 陕西巨子生物技术有限公司 | 医用止血敷料、制法及其应用 |
WO2023111959A1 (en) * | 2021-12-17 | 2023-06-22 | 3M Innovative Properties Company | Wound dressings and methods of making the same |
CN114470314B (zh) * | 2022-02-15 | 2022-10-14 | 海雅美生物技术(珠海)有限公司 | 一种重组人源化胶原蛋白凝胶敷料及其制备方法和应用 |
CN115400260B (zh) * | 2022-08-18 | 2023-08-15 | 湘雅生物医药(湖州)有限公司 | 一种含重组人源化胶原蛋白的修复凝胶及其制备方法 |
CN115444969B (zh) * | 2022-09-21 | 2023-07-18 | 湖南达丰医疗科技有限公司 | 一种重组ⅲ型类胶原蛋白敷料及其制备方法 |
CN115737902A (zh) * | 2022-11-07 | 2023-03-07 | 重庆正仁医疗器械有限公司 | 一种医用重组iii型人源化胶原蛋白凝胶 |
CN116688212B (zh) * | 2023-07-11 | 2024-03-08 | 湖南银华棠医药科技有限公司 | 一种具有修复抗衰作用的iii型重组胶原蛋白敷料及其制备方法和应用 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2517772A (en) | 1945-05-11 | 1950-08-08 | Parke Davis & Co | Neutralized oxidized cellulose products |
US3122479A (en) | 1957-11-14 | 1964-02-25 | David F Smith | Hemostatic surgical dressings |
GB1280631A (en) | 1968-07-09 | 1972-07-05 | Smith & Nephew | Adhesive materials |
US5936035A (en) * | 1988-11-21 | 1999-08-10 | Cohesion Technologies, Inc. | Biocompatible adhesive compositions |
CA2033046C (en) | 1990-01-12 | 1999-08-03 | Lowell Saferstein | Process for preparing a neutralized oxidized cellulose product and its method of use |
US5593859A (en) | 1991-10-23 | 1997-01-14 | Thomas Jefferson University | Synthesis of human procollagens and collagens in recombinant DNA systems |
GB9206504D0 (en) | 1992-03-25 | 1992-05-06 | Jevco Ltd | Heteromorphic sponges as wound implants |
US5667839A (en) | 1993-01-28 | 1997-09-16 | Collagen Corporation | Human recombinant collagen in the milk of transgenic animals |
GB2314842B (en) * | 1996-06-28 | 2001-01-17 | Johnson & Johnson Medical | Collagen-oxidized regenerated cellulose complexes |
US20020015724A1 (en) * | 1998-08-10 | 2002-02-07 | Chunlin Yang | Collagen type i and type iii hemostatic compositions for use as a vascular sealant and wound dressing |
FR2783429B1 (fr) * | 1998-09-18 | 2002-04-12 | Imedex Biomateriaux | Materiau collagenique bicomposite,son procede d'obtention et ses applications therapeutiques |
WO2001064258A1 (en) * | 2000-03-03 | 2001-09-07 | Syntacoll Ag | Agent for the treatment of wounds |
US6309454B1 (en) | 2000-05-12 | 2001-10-30 | Johnson & Johnson Medical Limited | Freeze-dried composite materials and processes for the production thereof |
GB2380135B (en) * | 2001-09-27 | 2005-01-12 | Johnson & Johnson Medical Ltd | Therapeutic wound dressing |
US20040106344A1 (en) * | 2002-06-28 | 2004-06-03 | Looney Dwayne Lee | Hemostatic wound dressings containing proteinaceous polymers |
PL207044B1 (pl) * | 2002-09-11 | 2010-10-29 | Johnson & Johnson Medical Ltd | Materiał opatrunkowy na rany zawierający kompleks utlenionej celulozy ze srebrem, opatrunek zawierający ten materiał, oraz zastosowanie kompleksu do wytwarzania materiału opatrunkowego |
EP1605862A4 (en) * | 2003-02-28 | 2008-09-03 | Fibrogen Inc | COLLAGEN COMPOSITIONS AND BIOMATERIALS |
WO2004088120A2 (de) * | 2003-04-01 | 2004-10-14 | Avl List Gmbh | Brennkraftmaschine mit kolbeneinspritzpumpe |
JP4896714B2 (ja) * | 2003-06-20 | 2012-03-14 | ジョンソン・アンド・ジョンソン・メディカル・リミテッド | 抗酸化性の創傷用包帯材料 |
GB2408206B (en) * | 2003-11-18 | 2007-11-28 | Johnson & Johnson Medical Ltd | Antioxidant and antimicrobial wound dressing materials |
GB2402882B (en) * | 2003-06-20 | 2007-03-28 | Johnson & Johnson Medical Ltd | Antioxidant wound dressing materials |
-
2005
- 2005-12-09 GB GB0525130A patent/GB2433029A/en not_active Withdrawn
-
2006
- 2006-11-17 CA CA2568455A patent/CA2568455C/en active Active
- 2006-12-08 ES ES06256271T patent/ES2373676T3/es active Active
- 2006-12-08 US US11/608,553 patent/US7833790B2/en active Active
- 2006-12-08 EP EP06256271A patent/EP1795210B1/en active Active
- 2006-12-08 JP JP2006332282A patent/JP5160081B2/ja active Active
- 2006-12-08 AU AU2006249270A patent/AU2006249270B8/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
AU2006249270A1 (en) | 2007-06-28 |
CA2568455A1 (en) | 2007-06-09 |
EP1795210A3 (en) | 2007-09-05 |
GB0525130D0 (en) | 2006-01-18 |
AU2006249270A8 (en) | 2012-10-25 |
CA2568455C (en) | 2014-01-14 |
EP1795210A2 (en) | 2007-06-13 |
EP1795210B1 (en) | 2011-11-02 |
AU2006249270B2 (en) | 2012-10-11 |
US20070154530A1 (en) | 2007-07-05 |
JP2007160092A (ja) | 2007-06-28 |
US7833790B2 (en) | 2010-11-16 |
ES2373676T3 (es) | 2012-02-07 |
GB2433029A (en) | 2007-06-13 |
AU2006249270B8 (en) | 2012-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5160081B2 (ja) | 酸化セルロースおよびヒト組換えコラーゲンを含有している創傷包帯 | |
US20170319736A1 (en) | Compositions For Wound Treatment | |
Mir et al. | Synthetic polymeric biomaterials for wound healing: a review | |
JP4401438B2 (ja) | 慢性創傷治癒のための酸化セルロースおよびその複合体の使用 | |
US20190151495A1 (en) | Composite biomaterials with controlled release of active ingredient, preparation process and uses | |
US8461410B2 (en) | Wound dressing materials comprising complexes of anionic polysaccharides with silver | |
CA2928336C (en) | Bioactive collagen biomaterials and methods for making | |
JP2007511313A (ja) | 抗酸化性および抗菌性を有する創傷ドレッシング材料 | |
JP2010527673A (ja) | 癒合における新規活性成分及びその使用 | |
JPH11146909A (ja) | 緩衝化された創傷ドレツシング材料 | |
GB2402882A (en) | Bioabsorbable wound dressing containing an antioxidant dye | |
JP2005537882A (ja) | 陰イオン多糖と銀の複合体を含む創傷包帯材料 | |
Chinta et al. | Natural polymer based hydrogel systems for wound management | |
Kumar et al. | New frontiers in wound-dressings: An interdisciplinary perspective | |
Bibire et al. | Biopolymers for Surgical Applications. Coatings 2022, 12, 211 | |
GB2444323A (en) | Cellular protein sheet material | |
JP2001212227A (ja) | 創傷被覆材 | |
JP2001212223A (ja) | 創傷被覆材 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20071130 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20081017 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090910 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120522 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120802 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20121127 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20121212 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5160081 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20151221 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |